ClinicalTrials.gg
TerminatedNCT03062540HONORUpdated May 22, 2024Results posted

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

A Phase 3 interventional study of TNX-102 SL and Placebo SL Tablet in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Terminated at 44 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
103rd of 1,491
358 · median 65
Started
2017
with 73 others
Phase 3
64 of 1,664
8 open now
Registered
748th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 103rd largest by enrollment of the 1,491 interventional ones that give a count, is one of 74 that started in 2017, is one of 64 in phase 3, and was the 748th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.

03

Conditions studied

  • PTSD

Keywords

  • PTSD
  • Military-related PTSD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 75 years of age, who have served in any branch of the military.
  • Diagnosed with current PTSD as determined by the Clinician-Administered PTSD Scale (CAPS-5) for .
  • Index trauma(s) resulting in PTSD must meet DSM-5 criterion A for PTSD as described in CAPS-5, have occurred in 2001 or later, be military service related.
  • Willing to refrain from use of all other formulations of cyclobenzaprine.
  • Willing and able to refrain from antidepressants and other excluded medications.
  • Capable of reading and understanding English and able to provide written .
  • If female, either not of or practicing a medically acceptable method of throughout the study.
  • Willing and able to comply with all protocol-specified requirements.

Exclusion criteria

Exclusion Criteria:

  • Increased risk of suicide, based on the investigator's judgment that is of a severity that is not appropriate for outpatient management, or that warrants additional therapy excluded by the protocol.
  • Significant (e.g., moderate or severe) comorbid traumatic brain injury (TBI) by history.
  • Severe depressive symptoms at screening or baseline.
  • laboratory abnormalities based on screening laboratory tests and/or medical history in the investigator's opinion.
  • Use of antidepressant medication within 2 months of baseline.
  • Female patients who are pregnant or lactating.
  • History of serotonin syndrome, severe allergic reaction or bronchospasm or known to cyclobenzaprine or the .
  • Seizure disorder.
  • Patients with a (BMI) > 45.
  • Has received any other drug within 30 days before Screening.
  • Previous participation in any other study with TNX-102 SL.
  • Family member of investigative staff.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
358 participants (actual)

Study arms

  • Experimental
    TNX-102 SL Tablet, 5.6 mg

    2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.

    Drug: TNX-102 SL

  • Placebo comparator
    Placebo SL Tablet

    2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.

    Drug: Placebo SL Tablet

Interventions

  • Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks

    Also known as: Low dose cyclobenzaprine sublingual tablets

  • DrugPlacebo SL Tablet

    Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks

    Also known as: Placebo sublingual tablets

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Total Clinician Administered PTSD Scale (CAPS-5) for DSM-5 at Week 12.

    To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the Clinician Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (CAPS-5) total symptom severity score in a 12-week study. Score ranges from 0 to 80 with lower scores indicating less severe PTSD symptoms.

    Time frame: Day 0 and Week 12

Secondary outcomes

  1. Clinical Global Impression - Improvement From Initiation of Treatment (CGI-I) Score After 12 Weeks of Treatment.

    To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the CGI-I score after 12 weeks of treatment. Score ranges from 1 to 7. 1 = Very much improved. 2 = Much improved. 3 = Minimally improved. 4 = No change. 5 = Minimally worse. 6 = Much worse. 7 = Very much worse.

    Time frame: Week 12

  2. Change From Baseline in the Disruption of Social Life/Leisure Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.

    To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in disruption of social life/leisure activities assessed with the SDS after 12 weeks of treatment. Score ranges from 0 to 10. Lower scores indicate less disruption to social life/leisure activities.

    Time frame: Day 0, Week 12.

  3. Change From Baseline in the Disruption of Work/School Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.

    To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in disruption of work/school activities assessed with the SDS after 12 weeks of treatment. Score ranges from 0 to 10. Lowers scores indicate less disruption to work/school activities.

    Time frame: Day 0, Week 12.

  4. Change From Baseline in Patients' Quality of Sleep Using the Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance Scale After 12 Weeks of Treatment.

    To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in quality of sleep using the PROMIS Sleep Disturbance scale after 12 weeks of treatment. Raw score is transformed to T-scores using published conversions. T-score ranges from 30 to 80 with lower scores indicating better sleep quality.

    Time frame: Day 0, Week 12.

07

Results

Posted May 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Started179179
Completed110120
Not completed6959

Outcome measures

PrimaryMean Change From Baseline in the Total Clinician Administered PTSD Scale (CAPS-5) for DSM-5 at Week 12.

To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the Clinician Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (CAPS-5) total symptom severity score in a 12-week study. Score ranges from 0 to 80 with lower scores indicating less severe PTSD symptoms.

Time frame:
Day 0 and Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Total Clinician Administered PTSD Scale (CAPS-5) for DSM-5 at Week 12.
units on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Mean Change From Baseline in the Total Clinician Administered PTSD Scale (CAPS-5) for DSM-5 at Week 12.-15.2 ± 1.90-14.2 ± 1.80
SecondaryClinical Global Impression - Improvement From Initiation of Treatment (CGI-I) Score After 12 Weeks of Treatment.

To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the CGI-I score after 12 weeks of treatment. Score ranges from 1 to 7. 1 = Very much improved. 2 = Much improved. 3 = Minimally improved. 4 = No change. 5 = Minimally worse. 6 = Much worse. 7 = Very much worse.

Time frame:
Week 12
Reported as:
Least squares mean · score on a scale
Clinical Global Impression - Improvement From Initiation of Treatment (CGI-I) Score After 12 Weeks of Treatment.
score on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Clinical Global Impression - Improvement From Initiation of Treatment (CGI-I) Score After 12 Weeks of Treatment.2.6 ± 0.162.7 ± 0.15
SecondaryChange From Baseline in the Disruption of Social Life/Leisure Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.

To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in disruption of social life/leisure activities assessed with the SDS after 12 weeks of treatment. Score ranges from 0 to 10. Lower scores indicate less disruption to social life/leisure activities.

Time frame:
Day 0, Week 12.
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disruption of Social Life/Leisure Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.
units on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in the Disruption of Social Life/Leisure Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.-2.1 ± 0.38-1.7 ± 0.35
SecondaryChange From Baseline in the Disruption of Work/School Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.

To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in disruption of work/school activities assessed with the SDS after 12 weeks of treatment. Score ranges from 0 to 10. Lowers scores indicate less disruption to work/school activities.

Time frame:
Day 0, Week 12.
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disruption of Work/School Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.
units on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in the Disruption of Work/School Activities Assessed Using the Sheehan Disability Scale (SDS) After 12 Weeks of Treatment.-1.6 ± 0.46-1.3 ± 0.41
SecondaryChange From Baseline in Patients' Quality of Sleep Using the Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance Scale After 12 Weeks of Treatment.

To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the change from baseline in quality of sleep using the PROMIS Sleep Disturbance scale after 12 weeks of treatment. Raw score is transformed to T-scores using published conversions. T-score ranges from 30 to 80 with lower scores indicating better sleep quality.

Time frame:
Day 0, Week 12.
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patients' Quality of Sleep Using the Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance Scale After 12 Weeks of Treatment.
units on a scaleTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Change From Baseline in Patients' Quality of Sleep Using the Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance Scale After 12 Weeks of Treatment.-9.3 ± 1.60-6.7 ± 1.49

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNX-102 SL Tablet, 5.6 mg0/179 (0%)3/175 (1.7%)93/175 (53.1%)
Placebo SL Tablet0/179 (0%)5/176 (2.8%)21/176 (11.9%)
Most frequent serious events
Most frequent serious events
EventTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Suicidal IdeationPsychiatric disorders1/1751/176
Alcohol Withdrawal SyndromePsychiatric disorders1/1750/176
Femur FractureInjury, poisoning and procedural complications1/1750/176
Suicide AttemptPsychiatric disorders0/1751/176
Amaurosis fugaxEye disorders0/1751/176
CholangitisHepatobiliary disorders0/1751/176
RhabdomyolysisMusculoskeletal and connective tissue disorders0/1751/176
Most frequent other events
Most frequent other events
EventTNX-102 SL Tablet, 5.6 mgPlacebo SL Tablet
Hypoaesthesia OralGastrointestinal disorders70/1752/176
SomnolenceNervous system disorders27/17515/176
Product Taste AbnormalProduct Issues17/1754/176
Paraesthesia OralGastrointestinal disorders16/1751/176

Baseline characteristics

Age, Continuous
Age, Continuous(years)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Mean35.4 ± 8.2135.9 ± 7.6935.7 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Female152136
Male164158322
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
Hispanic or Latino353469
Not Hispanic or Latino144145289
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
American Indian or Alaska Native448
Asian7613
Native Hawaiian or Other Pacific Islander437
Black or African American313162
White122124246
More than one race4610
Unknown or Not Reported7512
Region of Enrollment
Region of Enrollment(participants)TNX-102 SL Tablet, 5.6 mgPlacebo SL TabletTotal
United States179179358
08

Study locations

44 sites
  • Phoenix
    Phoenix, Arizona 85032, United States
  • Little Rock
    Little Rock, Arkansas 72211, United States
  • Rogers
    Rogers, Arkansas 72758, United States
  • Beverly hills
    Beverly Hills, California 90210, United States
  • Glendale
    Glendale, California 91206, United States
  • Oakland
    Oakland, California 94607, United States
  • Oceanside
    Oceanside, California 92056, United States
  • Orange
    Orange, California 92868, United States
  • Riverside
    Riverside, California 92506, United States
  • San Diego
    San Diego, California 92123, United States
  • San Diego
    San Diego, California 92161, United States
  • Temecula
    Temecula, California 92591, United States
  • Colorado Springs
    Colorado Springs, Colorado 80910, United States
  • Cromwell
    Cromwell, Connecticut 06416, United States
  • Norwich
    Norwich, Connecticut 06360, United States
  • Washington, D.C.
    Washington, District of Columbia 20018, United States
  • Jacksonville
    Jacksonville, Florida 32256, United States
  • Lake City
    Lake City, Florida 32607, United States
  • Lauderhill
    Lauderhill, Florida 33319, United States
  • Maitland
    Maitland, Florida 32751, United States
  • Tampa
    Tampa, Florida 33609, United States
  • Atlanta
    Atlanta, Georgia 30341, United States
  • Chicago
    Chicago, Illinois 60640, United States
  • New Bedford
    New Bedford, Massachusetts 02740, United States
  • Flowood
    Flowood, Mississippi 39232, United States
  • St. Louis
    Saint Louis, Missouri 63141, United States
  • Missoula
    Missoula, Montana 59812, United States
  • Las Vegas
    Las Vegas, Nevada 89102, United States
  • Berlin
    Berlin, New Jersey 08009, United States
  • Cedarhurst
    Cedarhurst, New York 11516, United States
  • New York
    New York, New York 10128, United States
  • Canton
    Canton, Ohio 44718, United States
  • Cincinnati
    Cincinnati, Ohio 45219, United States
  • Dayton
    Dayton, Ohio 45417, United States
  • Oklahoma City
    Oklahoma City, Oklahoma 73103, United States
  • Downingtown
    Downingtown, Pennsylvania 19335, United States
  • Media
    Media, Pennsylvania 19063, United States
  • Charleston
    Charleston, South Carolina 29407, United States
  • Austin
    Austin, Texas 78754, United States
  • Dallas
    Dallas, Texas 75231, United States
  • Houston
    Houston, Texas 77098, United States
  • San Antonio
    San Antonio, Texas 78229, United States
  • Salem
    Salem, Virginia 24153, United States
  • Everett
    Everett, Washington 98201, United States
09

References and documents

Publications

  • Parmenter ME, Lederman S, Weathers FW, Davis LL, Vaughn B, Engels J, Sullivan GM. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024 Apr;334:115764. doi: 10.1016/j.psychres.2024.115764. Epub 2024 Feb 1. PubMed 38350291 ↗
  • Dunlop BW, Rakofsky JJ, Newport DJ, Mletzko-Crowe T, Barone K, Nemeroff CB, Harvey PD. Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):172-179. doi: 10.1097/JCP.0000000000001363. PubMed 33587394 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jul 2018, 16 months.

Results were first posted in May 2024, 5 years 9 months after primary completion. A results delay was requested in Sep 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2017
First posted
Feb 23, 2017
StartActual
Mar 27, 2017
Primary completionActual
Jul 27, 2018
CompletionActual
Jul 27, 2018
Results delay requested
Sep 9, 2019
Results first posted
May 22, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03062540
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Mar 27, 2017
Primary completion
Jul 27, 2018
Completion
Jul 27, 2018
Results posted
May 22, 2024
Last update
May 22, 2024

Study contacts

Greg Sullivan, MD
study director · Tonix Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion